Literature DB >> 34990601

Increased energy demand from anabolic-catabolic processes drives β-lactam antibiotic lethality.

Michael A Lobritz1, Ian W Andrews2, Dana Braff3, Caroline B M Porter4, Arnaud Gutierrez4, Yoshikazu Furuta5, Louis B G Cortes6, Thomas Ferrante7, Sarah C Bening4, Felix Wong4, Charley Gruber8, Christopher W Bakerlee4, Guillaume Lambert6, Graham C Walker8, Daniel J Dwyer9, James J Collins10.   

Abstract

β-Lactam antibiotics disrupt the assembly of peptidoglycan (PG) within the bacterial cell wall by inhibiting the enzymatic activity of penicillin-binding proteins (PBPs). It was recently shown that β-lactam treatment initializes a futile cycle of PG synthesis and degradation, highlighting major gaps in our understanding of the lethal effects of PBP inhibition by β-lactam antibiotics. Here, we assess the downstream metabolic consequences of treatment of Escherichia coli with the β-lactam mecillinam and show that lethality from PBP2 inhibition is a specific consequence of toxic metabolic shifts induced by energy demand from multiple catabolic and anabolic processes, including accelerated protein synthesis downstream of PG futile cycling. Resource allocation into these processes is coincident with alterations in ATP synthesis and utilization, as well as a broadly dysregulated cellular redox environment. These results indicate that the disruption of normal anabolic-catabolic homeostasis by PBP inhibition is an essential factor for β-lactam antibiotic lethality.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  antibiotic mechanism; antibiotics; bacterial metabolism; metabolomics; β-lactams

Mesh:

Substances:

Year:  2022        PMID: 34990601      PMCID: PMC8857051          DOI: 10.1016/j.chembiol.2021.12.010

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  2 in total

1.  Strain-specific predation of Bdellovibrio bacteriovorus on Pseudomonas aeruginosa with a higher range for cystic fibrosis than for bacteremia isolates.

Authors:  Claudia Saralegui; Cristina Herencias; Ana Verónica Halperin; Juan de Dios-Caballero; Blanca Pérez-Viso; Sergio Salgado; Val F Lanza; Rafael Cantón; Fernando Baquero; M Auxiliadora Prieto; Rosa Del Campo
Journal:  Sci Rep       Date:  2022-06-22       Impact factor: 4.996

2.  Comparative Studies to Uncover Mechanisms of Action of N-(1,3,4-Oxadiazol-2-yl)benzamide Containing Antibacterial Agents.

Authors:  George A Naclerio; Kenneth I Onyedibe; Caroline W Karanja; Uma K Aryal; Herman O Sintim
Journal:  ACS Infect Dis       Date:  2022-03-17       Impact factor: 5.578

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.